NASH, short for Non-Alcoholic SteatoHepatitis (NASH), can be cured effectively with some compensated Cirrhosis, as per the new guidance that is drafted by the Center for Drug Evaluation and Research (CDER) at the US Food and Drug Administration (FDA).

NASH is a growing concern which is often associated with type 2 diabetes and hypertension-related cases. There seems to be no particular treatment for the NASH, but according to the CDER, treating NASH cirrhosis in randomized, placebo-controlled, double-blind clinical trials, and recommends that sponsors should discuss proposed stratification factors with the agency before beginning phase 3 trials.